At-home colon cancer tests are genuinely good at detecting cancer, but their accuracy depends on which test you use and what you’re hoping to catch. The best-performing option, the stool DNA test (sold as Cologuard), detects about 94% of colorectal cancers. The simpler and more common FIT test catches roughly 70% to 75% of cancers in a single use, though its accuracy compounds over years of annual testing. Where both tests fall short is in finding precancerous polyps, the growths you ideally want to catch before they ever become cancer.
Three Types of At-Home Tests
There are three stool-based screening tests available, and they work in fundamentally different ways. The oldest is the guaiac-based fecal occult blood test (gFOBT), which uses a chemical reaction to detect blood in your stool. It’s the least sensitive of the three, catching only 50% to 75% of cancers depending on the study. Newer high-sensitivity versions perform better than the original, but there’s still considerable uncertainty around their exact detection rates.
The fecal immunochemical test (FIT) is the most widely used stool test today. Instead of a chemical reaction, it uses antibodies designed to recognize human blood proteins. This makes it more specific to bleeding in the lower digestive tract and less likely to react to things like red meat or certain medications. FIT detects cancer with a sensitivity of roughly 70% to 100% depending on the blood concentration threshold used. At the most sensitive setting, where even trace amounts of blood trigger a positive result, FIT caught 100% of colorectal cancers in studies of symptomatic patients.
The stool DNA test combines FIT’s blood detection with analysis of DNA shed by abnormal cells in your colon. Cancer cells and precancerous growths release altered genetic material into stool, and the test looks for specific patterns of DNA changes alongside blood. A large study of more than 20,000 people published in the New England Journal of Medicine found this next-generation test detected 93.9% of colorectal cancers. That’s the highest single-use sensitivity of any at-home option.
Where These Tests Struggle
The real limitation isn’t cancer detection. It’s catching the precancerous growths called adenomas and polyps that haven’t yet turned malignant. This matters because the entire point of screening is to find and remove these growths before they become dangerous.
FIT detects only about 20% to 25% of advanced adenomas (the larger, more concerning polyps) and less than 5% of a type called sessile serrated polyps. The stool DNA test does better, catching about 43% of advanced precancerous lesions overall. Its sensitivity improves with polyp size: 42% to 50% for polyps one centimeter or larger, 63% to 67% for those over two centimeters, and 70% to 80% for the largest polyps over three centimeters. Still, a coin-flip chance of missing a large precancerous growth is a meaningful gap.
The gFOBT performs worst of all for precancerous detection, finding only 6% to 17% of advanced adenomas. If catching polyps early is your priority, no stool test comes close to colonoscopy.
How They Compare to Colonoscopy
Colonoscopy is the reference standard because it lets a doctor visually inspect the entire colon and remove polyps during the same procedure. Its sensitivity for both cancer and polyps is exceptionally high when performed by a skilled endoscopist. That said, colonoscopy isn’t perfect either. Detection rates vary surprisingly widely between doctors, with adenoma detection rates ranging from about 5% to 50% across endoscopists in clinical studies. The quality of your colonoscopy depends heavily on who performs it.
The practical tradeoff is straightforward. A colonoscopy gives you one thorough look every ten years. Stool tests trade lower per-test sensitivity for frequent retesting. FIT is done every year, gFOBT every year, and the stool DNA test every three years. A cancer that a single FIT might miss in year one has another chance of being caught in year two or three. Over a decade of annual testing, FIT’s cumulative detection rate climbs substantially.
False Positives Are Common
A positive result on any stool test does not mean you have cancer. In fact, most positive results turn out to be false alarms. One study examining real-world follow-up after positive Cologuard results found that 61.5% of patients who went on to get a colonoscopy had no significant findings. Only about 38.5% of positive results corresponded to meaningful lesions.
False positives happen because these tests react to any bleeding or (in the case of the DNA test) any genetic changes in the colon. Hemorrhoids, inflammation, benign polyps, and other non-cancerous conditions can all trigger a positive result. The FIT test’s specificity runs between roughly 90% and 95% depending on the threshold used, meaning 5% to 10% of people without cancer or significant polyps will still get a positive result. The stool DNA test has a specificity of about 92.7% for people with no significant findings, which is slightly lower than FIT alone, meaning it produces somewhat more false positives.
A false positive isn’t harmless. It means you’ll need a follow-up colonoscopy, with the associated preparation, time, and potential cost.
What Happens After a Positive Result
Every positive stool test requires a follow-up colonoscopy to determine what actually caused the result. This is not optional. The test itself cannot tell you whether you have cancer, a polyp, or just a hemorrhoid that bled. It only tells you something abnormal was detected.
Follow-through is a real problem. Research on real-world Cologuard use found that only 44% of patients with a positive result actually completed their follow-up colonoscopy. A screening test, no matter how accurate, provides zero benefit if you don’t act on the result.
One financial concern worth knowing about: a colonoscopy performed after a positive stool test has historically been classified as “diagnostic” rather than “screening,” which can mean higher out-of-pocket costs. For Medicare beneficiaries, Congress passed legislation in 2020 to phase out this cost-sharing gap between 2022 and 2030. Private insurance coverage varies, but advocacy groups like the American Gastroenterological Association have pushed to require all insurers to cover what they call the “full screening continuum,” including follow-up colonoscopies triggered by positive stool tests.
Which Test Is Right for You
Current guidelines from the U.S. Preventive Services Task Force recommend that adults ages 45 to 75 be screened for colorectal cancer. Any of the approved methods counts, and the best test is whichever one you’ll actually do consistently.
If you want the highest single-test accuracy from home, the stool DNA test detects 94% of cancers and 43% of advanced precancerous lesions. You repeat it every three years. The downside is a higher false-positive rate and, depending on your insurance, higher cost.
If you prefer simplicity and lower cost, FIT is done annually and catches 70% to 100% of cancers per use depending on the sensitivity threshold. Its real strength is cumulative: yearly testing over a decade gives cancer multiple chances to be detected. It also produces fewer false positives than the DNA test.
The gFOBT is largely being replaced by FIT in clinical practice because FIT is more sensitive and doesn’t require dietary restrictions before testing. If you’re still being offered a gFOBT, it’s worth asking about switching to FIT.
No stool test replaces colonoscopy for people at higher risk due to family history, inflammatory bowel disease, or prior polyps. For average-risk adults, though, at-home tests are a legitimate and effective screening option, provided you commit to the recommended schedule and follow up on any positive result.